Quick View
| Metric | Current Period | Same Period of Previous Year | YoY |
|---|---|---|---|
| Revenue | ¥11.32B | ¥10.97B | +3.2% |
| Operating Income | ¥1.33B | ¥1.37B | −2.8% |
| Ordinary Income | ¥1.40B | ¥1.43B | −1.9% |
| Net Income | ¥0.95B | ¥0.98B | −2.7% |
| ROE | 4.9% | 5.2% | - |
Executive Summary
The cumulative results for Q3 were characterized by higher revenue but lower profit, as revenue growth failed to absorb the increase in expenses, resulting in a decline in profit margins. Revenue increased to ¥11.32B (+3.2% YoY), while Operating Income declined to ¥1.33B (△2.8%), Ordinary Income to ¥1.40B (△1.9%), and Net Income attributable to owners of the parent to ¥0.95B (△1.7%). The primary factor was that deterioration in the profit margin of the Medical Gas-Related Business outweighed the growth of the Home Healthcare-Related Business, thereby reducing consolidated profits.
Factors Affecting Performance
【Revenue】Revenue increased 3.2% YoY to ¥11.32B. By segment, the Home Healthcare-Related Business was the largest and fastest-growing business, with revenue of ¥5.37B (47.5% composition ratio, +7.7% YoY), driving overall revenue growth. Meanwhile, the Medical Gas-Related Business was virtually flat at ¥2.94B (26.0% composition ratio, +0.1% YoY), while the Medical Gas Equipment Construction-Related Business declined to ¥1.11B (9.8% composition ratio, △11.4% YoY). The Nursing Care and Welfare-Related Business and Facility Care-Related Business posted modest revenue increases to ¥0.90B (+1.9% YoY) and ¥0.26B (+4.7% YoY), respectively.
【Profit and Loss】Operating Income declined 2.8% YoY to ¥1.33B, and the Operating Margin contracted by approximately 70bp to 11.8% from approximately 12.5% in the same period of the previous year. Segment profit in the Medical Gas-Related Business fell significantly to ¥0.32B, down △29.2% YoY, weighing on consolidated earnings. The Home Healthcare-Related Business secured higher profit of ¥0.74B (+17.5% YoY), but this alone was insufficient to offset profit declines in other businesses. Ordinary Income was ¥1.40B (△1.9% YoY), with Non-Operating Income of ¥0.09B, primarily consisting of ¥0.05B in dividend income, supplementing core operating profit. Extraordinary items were limited, consisting of a ¥0.01B loss on disposal of fixed assets, and had a limited impact on Profit Before Tax of ¥1.39B. Net Income was ¥0.95B (△1.7% YoY), resulting in higher revenue but lower profit overall.
Segment Analysis
The Home Healthcare-Related Business is the core of company-wide growth and earnings, with revenue of ¥5.37B (47.5% composition ratio, +7.7% YoY) and profit of ¥0.74B (+17.5% YoY, 13.8% margin). The Medical Gas-Related Business recorded revenue of ¥2.94B (26.0% composition ratio, +0.1% YoY), while profit declined significantly to ¥0.32B (△29.2% YoY, 10.9% margin). The Medical Gas Equipment Construction-Related Business posted revenue of ¥1.11B (△11.4% YoY) and profit of ¥0.16B (△5.0% YoY, 14.2% margin), maintaining the highest profit margin company-wide despite lower revenue and profit. The Nursing Care and Welfare-Related Business recorded revenue of ¥0.90B (+1.9% YoY) and profit of ¥0.02B (△38.3% YoY), resulting in higher revenue but lower profit, while the Facility Care-Related Business posted revenue of ¥0.26B (+4.7% YoY) and reduced its loss to ¥0.003B. Overall, the structural feature of the current period was the contrast between the Home Healthcare-Related Business, which drove revenue growth, and the Medical Gas-Related Business, where profit margins deteriorated.
Key Financial Indicators
【Profitability】The Operating Margin of 11.8% contracted by approximately 70bp from approximately 12.5% in the same period of the previous year, while the Net Profit Margin was 8.4%. The Gross Margin was 50.0% and the SG&A Expense Ratio was 38.3%, indicating that the SG&A burden continued to weigh on profit margins despite revenue growth.【Cash Flow Quality】Days Sales Outstanding were 66 days, indicating an increasing working capital burden associated with higher revenue. Inventories were ¥0.31B, equivalent to only 1.2% of total assets, and inventory risk was limited.【Investment Efficiency】ROE was 4.9% (DuPont decomposition: Net Profit Margin of 8.4% × Total Asset Turnover of 0.44x × Financial Leverage of 1.31x), with low Total Asset Turnover being the primary constraint on capital efficiency. The ratio of cash and deposits to total assets was high at 41.6%, which was one factor suppressing asset efficiency.【Financial Soundness】The Equity Ratio was high at 76.1%, while the Current Ratio was approximately 316% and the Debt-to-Equity Ratio was 0.31x, indicating a conservative financial structure.
Cash Flow Analysis
The current disclosure does not include figures from the cash flow statement, and therefore direct evaluations of Operating Cash Flow (OCF), Investing Cash Flow, and Financing Cash Flow cannot be performed. However, movements in the balance sheet indicate that cash and deposits were ¥10.73B, remaining almost flat compared with ¥10.63B in the previous year, suggesting that liquidity was maintained at a stable level. Meanwhile, accounts receivable and notes receivable totaled ¥2.72B, and collection days extended to 66 days alongside revenue growth, indicating the possibility that cash conversion is lagging revenue growth. Investment securities totaled ¥3.79B, up from ¥2.97B in the previous year, indicating that a portion of surplus funds was allocated to securities investments. Overall, liquidity concerns are limited; however, if the pace of increase in accounts receivable exceeds revenue growth, the company’s actual cash-generation capacity will need to be verified.
Quality of Earnings
The ¥0.07B difference between Ordinary Income of ¥1.40B and Operating Income of ¥1.33B was primarily attributable to Non-Operating Income of ¥0.09B, consisting of ¥0.05B in dividend income and ¥0.03B in interest income. Both are financial income and do not represent the earnings power of the core business. Extraordinary items were limited to Extraordinary Income of ¥0.00B and Extraordinary Losses of ¥0.01B, consisting of a loss on disposal of fixed assets, and had almost no impact on Profit Before Tax of ¥1.39B. Accordingly, the difference between Ordinary Income and Profit Before Tax was small. Comprehensive Income was ¥1.13B, exceeding Net Income attributable to owners of the parent of ¥0.95B, primarily due to a ¥0.19B increase in valuation difference on available-for-sale securities. This divergence resulted from fluctuations in the market prices of the investment securities held and should be considered separately from the profitability of the core business. Overall, the quality of current-period earnings can be assessed as solid, with limited uplift from extraordinary factors and earnings generally reflecting recurring business results.
Earnings Forecast and Guidance
Progress against the full-year forecast was 74.2% for Revenue, 64.4% for Operating Income, 65.5% for Ordinary Income, and 64.2% for Net Income. While Revenue was close to the standard progress rate of 75%, profit items were approximately 10 points lower. To achieve the full-year forecast, Q4 requires Revenue of ¥3.94B and Operating Income of ¥0.74B, equivalent to approximately 55% of cumulative Q3 Operating Income. The gap between revenue and profit progress suggests downside risk if deterioration in the profit margin of the Medical Gas-Related Business continues, making the extent of improvement in the Q4 cost structure the key to progress.
Shareholder Returns
The Q2 dividend was ¥45 per share, with 50% of the full-year company forecast dividend of ¥90 already paid. The calculated Payout Ratio is approximately 19.0%, based on forecast full-year Net Income of ¥1.476B and forecast dividends of ¥90 using the average number of shares outstanding during the period, indicating a high level of sustainability when measured solely against dividends. Given the conservative financial structure, including an Equity Ratio of 76.1% and a Current Ratio of approximately 316%, dividend payments are not placing pressure on financial soundness. The low Payout Ratio suggests a capital policy that retains capacity for future investment and additional shareholder returns.
Risk Factors
-
Deterioration in the profit margin of the Medical Gas-Related Business: Segment profit declined △29.2% YoY, and the profit margin remained at 10.9%. Price competition and increases in raw material and personnel costs may be having an impact, making the recovery of business profitability a key issue for achieving the full-year forecast.
-
Growth dependence on the Home Healthcare-Related Business: This business accounts for 47.5% of revenue and is the center of consolidated growth. Changes in the medical and long-term care fee reimbursement systems and the ability to secure personnel have a significant impact on performance.
-
Prolonged collection of accounts receivable: Days Sales Outstanding was 66 days, and the working capital burden is increasing relative to revenue growth. Changes in collection terms and the composition of business partners should be continuously monitored.
Industry Benchmark (For Reference; Compiled by the Company)
Industry Benchmark (trading)
Profitability and Returns
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Operating Margin | 11.8% | 3.3% (1.8%–5.0%) | +8.4pt |
| Net Profit Margin | 8.4% | 3.1% (1.4%–6.3%) | +5.3pt |
The company’s profitability is significantly above the industry median, with both its Operating Margin and Net Profit Margin ranking at high levels within the industry.
Growth and Capital Efficiency
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Revenue Growth Rate (YoY) | 3.2% | 5.2% (-4.1%–8.6%) | −2.0pt |
The Revenue Growth Rate was slightly below the industry median, indicating a relatively slower growth pace compared with the company’s high profitability.
Source: Compiled by the Company
Key Takeaways from the Earnings Results
-
The Home Healthcare-Related Business continued to achieve double-digit growth in both revenue and profit, strengthening its structural role as the driver of consolidated performance. Meanwhile, deterioration in the profit margin of the Medical Gas-Related Business pushed down the consolidated profit margin, and the contrasting performance of the two businesses was a key feature of the earnings results.
-
Progress against the full-year forecast was generally on track for Revenue at 74.2%, while profit items remained in the 64% range, indicating a delay in progress. Whether the cost structure improves in Q4 will be the determining factor in achieving the full-year forecast.
-
The financial structure remained conservative, with an Equity Ratio of 76.1% and a Current Ratio of approximately 316%, while the Payout Ratio remained low at approximately 19%. The allocation of funds to cash and investment securities is suppressing Total Asset Turnover and ROE (4.9%), leaving room for improvement in capital efficiency as a structural area of focus.
This report is an earnings analysis document automatically generated by AI based on XBRL earnings summary data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly available earnings data. Investment decisions should be made at your own discretion and responsibility, after consulting a professional advisor as necessary.
---End of Report---
AI Financial Analysis
Executive Summary
FY2026 Q3 performance was resilient at the revenue line but showed a modest deterioration in profitability as expense growth and weaker performance in several service lines outweighed strong home-health earnings. Revenue rose 3.2% year on year to ¥113.20bn. Gross profit increased 2.2% to ¥56.65bn, trailing revenue growth. Operating income declined 2.8% to ¥13.33bn, while ordinary income fell 1.9% to ¥14.02bn. Net income attributable to owners declined 1.7% to ¥9.48bn. The gross margin contracted by approximately 52bp year on year to 50.0%. The operating margin contracted by approximately 73bp to 11.8%, remaining in the good 8-15% profitability range but moving below the prior-year level. The net profit margin was 8.4%, down by approximately 56bp year on year and still within the good 5-10% range. SG&A expenses rose 3.8% to ¥43.32bn, faster than revenue growth, increasing the SG&A-to-sales ratio by approximately 23bp to 38.3%. Home healthcare was the principal earnings offset, with segment profit rising 17.5% to ¥7.43bn on revenue growth of 7.7%. Conversely, medical gas, care-and-welfare, and construction-related operations recorded profit declines, limiting consolidated operating leverage. Non-operating income of ¥0.88bn was supported primarily by ¥0.48bn of dividend income and ¥0.26bn of interest income. Interest expense was only ¥0.12bn, and interest coverage of 113.1x indicates that financing costs do not constrain earnings. Balance-sheet liquidity is exceptionally strong, with cash and deposits of ¥107.31bn, a 316.3% current ratio, and a 309.3% quick ratio. Full-year revenue progress is broadly in line at 74.2% of forecast, but operating-income progress of 64.4% is 10.6 percentage points below the normal 75% Q3 run rate. The full-year plan therefore requires a material fourth-quarter profit recovery, especially in medical gas and care-related businesses, to achieve the forecast 4.4% operating-income growth. The interim dividend of ¥45 per share and planned full-year DPS of ¥90 indicate a conservative shareholder-return burden relative to earnings.
Profitability Analysis
The reported annualized DuPont ROE is 6.5%, decomposed into an 8.4% net profit margin, 0.586x asset turnover, and 1.31x financial leverage. The largest structural constraint on ROE is low asset turnover rather than leverage, reflecting a balance sheet with substantial cash, investment securities, and owned property. Financial leverage is conservative and does not artificially elevate returns. Profitability pressure in the quarter came from margin compression: gross margin declined about 52bp and operating margin declined about 73bp year on year. Revenue growth of 3.2% was insufficient to absorb SG&A growth of 3.8%, producing negative operating leverage. The operating-margin decline was driven by a combination of slower gross-profit growth and a higher SG&A burden. In segment terms, home healthcare delivered the strongest incremental contribution, with revenue of ¥53.72bn (+7.7% YoY), operating profit of ¥7.43bn (+17.5%), and a 13.8% margin versus 12.7% a year earlier. It is the core business by operating-income contribution, accounting for approximately 56% of consolidated operating income. Medical gas revenue was essentially flat at ¥29.41bn (+0.1%), while segment profit fell 29.2% to ¥3.21bn and margin compressed to 10.9% from 15.4%. Medical-gas equipment construction revenue declined 11.4% to ¥10.49bn, though its 15.0% segment margin remained the highest among the principal profitable segments; segment profit declined 4.9% to ¥1.57bn. Care-and-welfare revenue increased 1.9% to ¥8.96bn, but segment profit fell 38.3% to ¥0.21bn and margin declined to 2.3%. Facility-care revenue rose 4.7% to ¥2.63bn and its loss narrowed to ¥0.03bn from ¥0.06bn. Other businesses increased revenue 9.7% to ¥7.99bn and maintained segment profit near ¥0.94bn. The 6.5% annualized ROE is below the 8% benchmark, and improvement depends primarily on restoring operating margins and improving turnover of the cash- and investment-heavy asset base.
Growth Assessment
Revenue growth is supported chiefly by home healthcare, where sales expanded ¥3.84bn year on year, and by other businesses, which added ¥0.71bn. These gains offset a ¥1.35bn revenue decline in medical-gas equipment construction. Medical gas remained broadly stable in revenue but suffered a substantial earnings decline, making its margin recovery important for consolidated growth. Home healthcare's stronger revenue and margin trajectory provides the clearest evidence of favorable operating momentum. The care-and-welfare business achieved modest sales growth but its sharp profit decline indicates cost or mix pressure that should be monitored. Revenue reached 74.2% of the ¥152.60bn full-year forecast, close to the standard 75% Q3 progress rate. Operating income reached 64.4% of the ¥20.70bn full-year forecast, 10.6 percentage points below the standard rate and therefore requiring a stronger fourth quarter. Ordinary income progress is 65.5% against the ¥21.40bn forecast, modestly below the normal Q3 rate. Net income attributable to owners reached 64.2% of the ¥14.76bn forecast, also 10.8 percentage points below the standard 75% run rate. Achieving guidance requires fourth-quarter revenue of ¥39.40bn and operating income of ¥7.37bn, equivalent to a 18.7% quarterly operating margin, compared with the cumulative Q3 margin of 11.8%. This implied margin step-up makes the earnings plan dependent on seasonal effects and/or meaningful profitability recovery. Full-year guidance nevertheless calls for 1.0% revenue growth and 4.4% operating-income growth, implying management expects margin restoration rather than a major acceleration in sales growth.
Financial Health
The balance sheet is highly liquid and conservatively capitalized. Current assets of ¥140.41bn exceed current liabilities of ¥44.39bn by ¥96.02bn, producing a 316.3% current ratio and a 309.3% quick ratio. Cash and deposits of ¥107.31bn alone equal approximately 2.4 times current liabilities. Total equity increased ¥8.84bn year on year to ¥195.99bn, while total liabilities increased ¥2.98bn to ¥61.72bn. The debt-to-equity ratio of 0.31x is well below the 2.0x warning threshold and indicates low balance-sheet financial risk. Noncurrent liabilities of ¥17.33bn include a ¥9.14bn provision for directors' retirement benefits, up from ¥8.24bn a year earlier. Interest coverage of 113.1x confirms ample capacity to meet interest obligations. Accounts payable of ¥27.09bn broadly matched trade receivables of ¥27.20bn, limiting trade-working-capital funding pressure. Inventories rose ¥1.35bn, or 75.4%, to ¥3.13bn, although they remain only 1.2% of total assets. The increase warrants monitoring for product mix changes and inventory turnover discipline, but its absolute balance remains modest relative to liquidity. Investment securities rose ¥8.25bn, or 27.8%, to ¥37.92bn and now represent 14.7% of total assets. Together with ¥107.31bn of cash, the investment portfolio reinforces financial flexibility but also contributes to the low asset-turnover component of ROE. Property, plant and equipment totaled ¥67.96bn, including land of ¥36.46bn, which provides an asset base but increases dependence on effective utilization of owned facilities. Intangible assets were only 0.5% of total assets, and segment disclosures show no goodwill or impairment items.
Notable B/S Changes
Inventories: +¥1.35bn (+75.4%) to ¥3.13bn - growth substantially exceeded the 3.2% increase in revenue; monitor inventory turnover and demand alignment. Investment securities: +¥8.25bn (+27.8%) to ¥37.92bn - increased exposure to market-value movements and further contributes to low asset turnover. Total equity: +¥8.84bn (+4.7%) to ¥195.99bn - strengthening capital base and supporting very low leverage. Provision for directors' retirement benefits: +¥0.90bn (+10.9%) to ¥9.14bn - a meaningful noncurrent obligation within the liability structure. Accounts receivable: -¥1.51bn (-5.3%) to ¥27.20bn - favorable year-on-year balance movement, although DSO remains elevated at 66 days.
Cash Flow Quality
The increase in cash and deposits to ¥107.31bn from ¥106.26bn year on year supports the company's substantial liquidity reserve. Net income was ¥9.48bn, while comprehensive income was higher at ¥11.33bn, supported in part by positive valuation movements in securities. Investment securities increased by ¥8.25bn year on year, indicating that capital allocation toward financial investments is a relevant use of balance-sheet resources. Trade receivables declined ¥1.51bn year on year to ¥27.20bn, which is constructive for balance-sheet working-capital exposure. However, the quality alert identifies receivable days outstanding of 66 days, above the 60-day threshold. The root cause is that the receivable balance remains significant relative to the revenue base despite the year-on-year reduction. Institutional and healthcare-related customers can have structured billing and settlement cycles, but a 66-day DSO still elevates collection-cycle sensitivity. The impact is a potentially slower conversion of reported revenue into cash and a need to monitor receivable aging, payment terms, and overdue balances. Inventory increased more rapidly than sales, rising 75.4% against 3.2% revenue growth, which is a secondary working-capital item to monitor. The modest inventory balance relative to total assets limits the immediate financial impact, but sustained growth at this pace could weaken cash conversion. The combination of declining receivables and higher inventory suggests that working-capital management should be assessed by business line, particularly in equipment construction and medical-gas operations.
Dividend Sustainability
The company paid an interim DPS of ¥45 and forecasts full-year DPS of ¥90. The calculated interim payout ratio is 16.2%, indicating a low immediate earnings burden. Based on the full-year EPS forecast of ¥472.57 and planned DPS of ¥90, the forecast dividend payout ratio is approximately 19.0%. This is materially below the 60% sustainability benchmark. Retained earnings of ¥180.38bn and cash and deposits of ¥107.31bn provide a substantial capital buffer for the dividend. The conservative payout level leaves room for continued investment, balance-sheet resilience, and potential shareholder returns without relying on aggressive leverage. No change in treasury stock is evident at a level that would materially alter the dividend analysis. Dividend sustainability is therefore principally linked to maintaining profitability rather than financing capacity. The key earnings consideration is the need for fourth-quarter operating-margin recovery to achieve full-year profit guidance.
Risk Assessment
Business risks include Medical gas segment profitability weakened materially: revenue was flat at ¥29.41bn while segment profit fell 29.2% to ¥3.21bn, reducing its margin by roughly 450bp to 10.9%., Care-and-welfare profitability is thin and deteriorating: segment profit fell 38.3% to ¥0.21bn despite 1.9% revenue growth, leaving a 2.3% margin., Medical-gas equipment construction revenue declined 11.4% to ¥10.49bn, exposing the group to project timing and demand volatility in healthcare-facility investment., Healthcare and care-service operations face labor-cost, staffing availability, reimbursement, and procurement-cost pressures, particularly where segment margins are already low., Receivable days outstanding of 66 days exceeds the 60-day alert threshold, creating collection-cycle and counterparty-payment risk..
Financial risks include Operating-income progress is 64.4% at Q3, 10.6 percentage points below the normal 75% pace, requiring a substantial fourth-quarter margin recovery to achieve guidance., Inventory increased 75.4% year on year to ¥3.13bn, substantially faster than sales growth and requiring monitoring for turnover and demand alignment., Investment securities increased 27.8% to ¥37.92bn; valuation changes can affect comprehensive income and capital-market exposure., The large cash and investment balance supports liquidity but depresses asset turnover, constraining capital efficiency and annualized ROE..
Key concerns include Highest priority: execution risk around the implied fourth-quarter operating margin of approximately 18.7% needed to meet full-year operating-income guidance., High priority: whether home-health earnings growth can continue to offset margin pressure in medical gas and care-and-welfare operations., Moderate priority: 66-day DSO should be monitored despite the year-on-year reduction in receivables, as prolonged settlement cycles can delay cash realization., Moderate priority: inventory growth should normalize relative to revenue growth to avoid unnecessary working-capital absorption., Moderate priority: the 6.5% annualized ROE remains below the 8% benchmark, reflecting limited asset efficiency despite a strong capital position..
Investment Implications
Key takeaways include Revenue growth remains positive at 3.2%, led by home healthcare, but consolidated operating income declined 2.8%., Home healthcare is the core earnings engine, generating ¥7.43bn of segment profit and improving its margin to 13.8%., The balance sheet is exceptionally strong, with ¥107.31bn cash, a 316.3% current ratio, 0.31x debt-to-equity, and 113.1x interest coverage., Earnings guidance requires a pronounced fourth-quarter improvement because Q3 operating-income progress is only 64.4% versus a normal 75% pace., The planned ¥90 full-year DPS implies an approximately 19% forecast payout ratio and is supported by earnings, retained earnings, and liquidity..
Metrics to watch include Medical gas segment margin and profit recovery, Home healthcare revenue growth and segment margin sustainability, Q4 operating margin relative to the approximately 18.7% implied level needed for full-year guidance, Receivable days outstanding, receivable aging, and collection performance, Inventory growth and turnover, Investment securities balance and valuation movements, Annualized ROE and asset-turnover improvement.
Regarding relative positioning, The company combines good operating-margin and net-margin levels with unusually strong liquidity and conservative leverage. Its relative weakness is capital efficiency: the reported annualized 6.5% ROE is below the 8% benchmark because a large cash, securities, and property base holds asset turnover to 0.586x. Compared with a more leveraged healthcare-services operator, its financial-risk profile is lower, while the principal operating issue is restoring margins outside the expanding home-health business.